Sanofi, a French healthcare business, announced on Wednesday that the first research into a high-dose influenza vaccination with a COVID-19 mRNA booster had yielded good results.
Sanofi stated initial findings from a trial comparing Sanofi’s Fluzone High-Dosage Quadrivalent vaccine to Moderna’s COVID-19 mRNA experimental booster dose revealed that the vaccines had similar immunogenicity responses as well as a similar safety and tolerability profile.
“These positive results could facilitate the implementation of Northern Hemisphere influenza and COVID-19 booster vaccination campaigns, especially in this high-risk population,” said Dr. Michael Greenberg, North America Medical Head for Vaccines at Sanofi.
